rituximab

(redirected from Rituxan)
Also found in: Medical.
Related to Rituxan: Herceptin, Avastin

ri·tux·i·mab

 (rĭ-tŭk′sĭ-măb′)
n.
A chimeric monoclonal antibody used to treat certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and refractory rheumatoid arthritis.

[ri-, origin unknown + tu(mor) + -xi- (alteration of chi(meric), influenced by X, Greek letter chi) + m(onoclonal) a(nti)b(ody).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

rituximab

(rɪˈtʌksɪˌmæb)
n
a monoclonal antibody used to treat non-Hodgkin's lymphoma
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

rituximab

n rituximab m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
The most common (>=20%) adverse reactions observed with Rituxan Hycela in people with follicular lymphoma were infections, low white blood cell count (neutropenia), nausea, constipation, cough and fatigue.
According to the contract, Viropro will produce six monoclonal antibody products that are being developed by Oncobiologics, including generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux and a non-disclosed biotherapeutic used for cancer and immune-disease indications.
(Cambridge MA) said that their drug Rituxan failed as a treatment for lupus in a closely-watched study, potentially dashing hopes of a significant sales expansion for the blockbuster biotechnology medicine.
M2 PHARMA-March 30, 2017-Roche maintains Rituxan success with new formulation and Breakthrough designation
The partnerships's phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 (DCDT2980S, RG7593) and DCDS4501A (RG7596) each in combination with Rituxan (rituximab) in patients with relapsed or refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse large B-cell lymphoma.
Genentech Inc (South San Francisco CA) and Biogen Idec Inc's (Cambridge MA) cancer drug Rituxan reduced brain lesions in multiple sclerosis patients and cut their risk of relapse, offering a potential new way to slow the disease.
ENPNewswire-August 23, 2019--Amgen and Allergan Announce Positive Top-Line Results from Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan
Amgen (AMGN) and Allergan (AGN) announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan, compared to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma.
It was reported yesterday that the US Food and Drug Administration (USFDA) has granted approval to United States-based Pfizer's Ruxience (rituximab-pvvr), a biosimilar to Roche's cancer drug Rituxan (rituximab) for cancer treatment.